Lysosomal β-galactosidase and β-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus

Journal of Alzheimer's Disease

Volumn 24, Issue 4, 2011, Pages 785-797

  Tiribuzi, Roberto ^a   Orlacchio, Antonio ^b,c   Crispoltoni, Lucia ^a   Maiotti, Mariangela ^d   Zampolini, Mauro ^d   De Angelis, Massimiliano ^a   Mecocci, Patrizia ^a   Cecchetti, Roberta ^a   Bernardi, Giorgio ^b,c   Datti, Alessandro ^a   Martino, Sabata ^a   Orlacchio, Aldo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Ospedale S Giovanni Battista   (Italy)

Author keywords

Alzheimer's disease; diagnostic correlation; lysosomal glycohydrolases; type 2 diabetes

Indexed keywords

ALPHA MANNOSIDASE; BETA GALACTOSIDASE; BETA N ACETYLHEXOSAMINIDASE; HEMOGLOBIN A1C;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY FLUID; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME RELEASE; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UPREGULATION;

EID: 79959198484     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-100525     Document Type: Article

References (71)

1. Ferri CP, Prince M, Brayn C (2005) Global prevalence of dementia: a Delphi Consensus Study. Lancet 366, 2112-2117. (Pubitemid 41797645)
2. Jellinger KA (2006) Alzheimer 100 -highlights in the history of Alzheimer research. J Neural Transm 113, 1603-1623. (Pubitemid 44660049)
3. Patterson CJ, Feightner W, Garcia A, Hsiung GY,MacKnight C, Sadovnick AD (2008) Diagnosis and treatment of dementia: Risk assessment and primary prevention of Alzheimer disease. Can Med Assoc J 178, 548-556.
4. Ansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774-779. (Pubitemid 44622681)
5. Turner RS (2006) Alzheimers disease. Semin in Neurol 26, 499-506.
6. Ohyagi Y, Tabira T (2006) Intracellular amyloid beta-protein and its associated molecole in the pathogenesis of Alzheimers disease. Mini Rev Med Chem 6, 1075-1080. (Pubitemid 44524450)
7. Goldgaber D, Lerman MI, Mcbride OW(1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimers disease. Science 235, 877-880. (Pubitemid 17019124)
8. Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Othman LB, Dridi H, Bennamou S, Limen K (2008) CSF-amyloid 1-42 and tau in Tunisian patients with Alzheimers disease: the effect of APOE-4 allele. Neurosci Lett 440, 145-149.
9. Lewczuk P,Wiltfang J (2008) Neurochemical dementia diagnostics: state of the art and research perspectives. Proteomics 8, 1292-1301. (Pubitemid 351462934)
10. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, OKeefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL (2008) Imaging of amyloid beta in Alzheimers disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7, 129-135.
11. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
12. Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, Spenger C, Tsolaki M, Vellas B, Wahlund LO, Ward M (2009) AddNeuroMed Consortium AddNeuroMed -the European collaboration for the discovery of novel biomarkers for Alzheimers disease. Ann N Y Acad Sci 1180, 36-46.
13. Sims-Robinson C, Kim B, RoskoA, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6, 551-559.
14. Mattson MP (2004) Pathways towards and away from Alzheimers disease. Nature 430, 631-639. (Pubitemid 39061671)
15. Selkoe DJ (1991) The molecular pathology of Alzheimers disease. Neuron 6, 487-498.
16. Goedert M, Spillantini MG (2006) A century of Alzheimers disease. Science 314, 777-781.
17. Orlacchio A, Bernardi G, Orlacchio A, Martino S (2007)RNA interference as a tool for Alzheimers disease therapy. Mini Rev Med Chem 7, 1166-1176. (Pubitemid 350200223)
18. Costanzi E, Martino S, Persichetti E, Tiribuzi R, Massini C, Bernardi G, Orlacchio AN, Orlacchio A (2008) Effects of vtamin C on fibroblasts from sporadic Alzheimers disease patients. Neurochem Res 33, 2510-2515.
19. Martino S, di Girolamo I, Orlacchio A, Datti A, Orlacchio A (2009) MicroRNA implications across neurodevelopment and neuropathology. J Biomed Biotechnol 2009, 654346.
20. Haan MN (2006) Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimers disease. Nat Clin Pract Neurol 2, 159-166.
21. Strachan MWJ, Deary IJ, Ewing FME, Frier BM (1997) Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20, 438-445. (Pubitemid 27098239)
22. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB (2008) Insulin resistance and Alzheimers disease: molecular link & clinical implication. Curr Alz Res 5, 438-447.
23. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2009) Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 385, 193-197.
24. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551. (Pubitemid 41170713)
25. Li L, Ḧolscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56, 384-402. (Pubitemid 350166529)
26. Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as commo molecular foundation for type 2 diabetes and Alzheimers disease. Biochim Biophys Acta 1792, 482-496.
27. Janson J, Laedtke T, Parisi JE, OBrien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481. (Pubitemid 38174565)
28. Bradley W, Doble, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186.
29. Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimers disease: review and hypothesis. Neurobiol Aging 2, 190-198. (Pubitemid 43038542)
30. Nixon RA, Yang DS, Lee JH (2008) Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4, 590-599.
31. Adamec E, Mohan PS, Cataldo AM, Vonsattel JP, Nixon RA (2000) Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimers disease. Neuroscience 100, 663-675.
32. Nixon RA, Mathews PM, Cataldo AM (2001) The neuronal endosomal-lysosomal system in Alzheimers disease. J Alzheimers Dis 3, 97-107. (Pubitemid 32238256)
33. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
34. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Amyloid beta: the alternate hypothesis. Curr Alz Res 3, 75-80.
35. La Ferla FM, Green KN, Oddo S (2007) Intracellular amyloidbeta in Alzheimers disease. Nat Rev Neurosci 8, 499-509.
36. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimers disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157, 277-286. (Pubitemid 30641743)
37. Cataldo AM, Nixon RA (1990) Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci U S A 87, 3861-3865.
38. Hook Vivian YH, Kindy M, and Gregory H (2008) Inhibitors of cathepsin B improve memory and reduce A-42 in transgenic Alzheimers disease mice expressing the wild-type, but not the swedish mutant,-secretase app site. J Biol Chem 283, 7745-7753.
39. Cataldo AM, Barnett JL, Mann DM, Nixon RA (1996) Colocalization of lysosomal hydrolase and-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimers disease and Downs syndrome. Neuropathol Exp Neurol 55, 704-715. (Pubitemid 26187397)
40. Emiliani C, Urbanelli L, Racanicchi L, Orlacchio A, Pelicci G, Sorbi S, Bernardi G, Orlacchio A (2003) Up-regulation of glycohydrolases in Alzheimers disease fibroblasts correlates with Ras activation. J Biol Chem 278, 38453-38460. (Pubitemid 37221739)
41. Urbanelli L, Emiliani C, Massini C, Persichetti E, Orlacchio A, Pelicci G, Sorbi S, Hasilik A, Bernardi G, Orlacchio A (2008) Cathepsin D expression is decreased in Alzheimers disease fibroblasts. Neurobiol Aging 29, 12-22. (Pubitemid 350102710)
42. Maciejewski R, Burski K, Baj J, Madej B, Burdan F, Dabrowski A, Brakowiecki F (2001) Changes in pancreatic lysosomal enzymes activity as the potential factors leading to diabetic enteropathy. J Physiol Pharmacol 52, 823-834. (Pubitemid 34042364)
43. Waters PJ, Flynn MD, Corrall RJ, Pennock CA (1992) Increases in plasma lysosomal enzymes in type 1 (insulindependent) diabetes mellitus: relationship to diabetic complications and glycaemic control. Diabetologia 35, 991-995.
44. Burlina AB, Goi G, Fabi A, Lombardo A, Gaburro D, Tettamanti G (1987) Behaviour of some lysosomal enzymes in the plasma of insulin dependent diabetic patients during artificial pancreas treatment. Clin Biochem 20, 423-427. (Pubitemid 18035413)
45. Walkley SU (2009) Pathogenic cascades in lysosomal disease -Why so complex? J Inherit Metab Dis 32, 181-189.
46. Poon PY, Davis TM, Dornan TL, Turner RC (1983) Plasma N-acetyl-beta, D-glucosaminidase activities and glycaemia in diabetes mellitus. Diabetologia 24, 433-436. (Pubitemid 13057378)
47. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34, 939-944. (Pubitemid 14076461)
48. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12, 189-198.
49. Morris JC (1997) Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9, 173-176. (Pubitemid 28045357)
50. ChavesML, Camozzato AL, Godinho C, Kochhann R, Schuh A, de Almeida VL, Kaye J (2007) Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients. Alzheimer Dis Assoc Disord 21, 210-217. (Pubitemid 47367973)
51. American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 27, S5-S10.
52. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, Tammen H, Schulz-Knappe P, Speicher DW, Vitzthum F, Haab BB, Siest G, Chan DW. (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277. (Pubitemid 41192034)
53. Martino S, Tiribuzi R, Tortori A, Conti D, Visigalli I, Lattanzi A, Biffi A, Gritti A, Orlacchio A (2009) Specific determination of {beta}- Galactocerebrosidase activity via competitive inhibition of {beta}- Galactosidase. Clin Chem 55, 541-548.
54. Sopelsa AM, Severini MH, Da Silva CM, Tobo PR, Giugliani R, Coelho JC (2000) Characterization of beta-galactosidase in leukocytes and fibroblasts of GM1 gangliosidosis heterozygotes compared to normal subjects. Clin Biochem 33, 125-129. (Pubitemid 30212820)
55. Beccari T, Mancuso F, Costanzi E, Tassi C, Barone R, Fiumara A, Orlacchio A, Aisa MC, Orlacchio A (2000)-Hexosaminidase,-mannosidase and-mannosidase expression in serum from patients with carbohydrate deficient glycoprotein syndrome type I. Clin Chim Acta 302, 125-132.
56. Martino S, di Girolamo I, Cavazzin C, Tiribuzi R, Galli R, Rivaroli A, Valsecchi M, Sandhoff K, Sonnino S, Vescovi A, Gritti A, Orlacchio A (2009) Neural precursor cell cultures fromGM2gangliosidosis animal models recapitulate the biochemical and molecular hallmarks of the brain pathology. J Neurochem 109, 135-147.
57. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
58. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39, 561-565.
59. Schernthaner G (2010) Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 160, 8-19.
60. Holt OJ, GalloF, Griffiths GM (2006) Regulating secretory lysosomes. J Biochem 140, 7-12. (Pubitemid 44433540)
61. Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L (2007) Altered plasma cytokine levels in Alzheimers disease: correlation with the disease progression. Immunol Lett 30, 46-51. (Pubitemid 47625597)
62. Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2010) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol, Published online May 21. DOI 10.1007/s00592-010-0198-0
63. Hultberg B, Isaksson A, Agardh E, AgardhCD(1995) Plasma beta-hexosaminidase isoenzymes A and B exhibit different relations to blood glucose levels in a population of type 1 diabetic patients. Scand J Clin Lab Invest 55, 723-728.
64. Pitk̈anen E, Kyll̈astinen M, Koivula T, Hormila P (1980) beta-N-acetylglucosaminidase and beta-glucuronidase activities in insulin-dependent diabetic subjects with retinopathy. Diabetologia 18, 275-278. (Pubitemid 10134419)
65. Jung K, Pergande M, Schimke E, RatzmannKP, IliusA(1988) Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy. Clin Chem 34, 544-547.
66. Weitgasser R, Schnoell F, Gappmayer B, Kartnig I (1999) Prospective evaluation of urinary N-acetyl-beta-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 22, 1882-1886. (Pubitemid 29521878)
67. Wakabayashi M, Okada T, Kozutsumi Y, Matsuzaki K (2005) GM1 ganglioside-mediated accumulation of amyloid-protein on cell membranes. Biochem Biophys Res Commun 328, 1019-1023. (Pubitemid 40238737)
68. Barrier L, Ingrand S, Damjanac M, Rioux Bilan A, Hugon J, Page G (2007) Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimers disease. Neurobiol Aging 28, 1863-1872. (Pubitemid 47539690)
69. Yanagisawa K (2007) Role of gangliosides in Alzheimers disease. Biochim Biophys Acta 1768, 1943-1951.
70. Matsuzaki K, Kato K, Yanagisawa K (2010) Abeta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta 1801, 868-877.
71. Yamamoto N, Taniura H, Suzuki K (2010) Insulin inhibits Abeta fibrillogenesis through a decrease of the GM1 ganglioside-rich microdomain in neuronal membranes. J Neurochem 113, 628-636.